Dietary exposure to soy or whey proteins alters colonic global gene expression profiles during rat colon tumorigenesis by Xiao, Rijin et al.
BioMed  Central
Page 1 of 17
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Dietary exposure to soy or whey proteins alters colonic global gene 
expression profiles during rat colon tumorigenesis
Rijin Xiao1,2, Thomas M Badger1,2 and Frank A Simmen*1,2
Address: 1Arkansas Children's Nutrition Center, 1120 Marshall Street, Little Rock, AR, 72202, USA and 2Department of Physiology and Biophysics, 
University of Arkansas for Medical Sciences, Little Rock, AR, 72202, USA
Email: Rijin Xiao - XiaoRijin@uams.edu; Thomas M Badger - BadgerThomasM@uams.edu; Frank A Simmen* - SimmenFrankA@uams.edu
* Corresponding author    
colon cancersoywheygene expression profilingneuro-endocrinemicroarrayrat
Abstract
Background: We previously reported that lifetime consumption of soy proteins or whey proteins
reduced the incidence of azoxymethane (AOM)-induced colon tumors in rats. To obtain insights
into these effects, global gene expression profiles of colons from rats with lifetime ingestion of
casein (CAS, control diet), soy protein isolate (SPI), and whey protein hydrolysate (WPH) diets
were determined.
Results: Male Sprague Dawley rats, fed one of the three purified diets, were studied at 40 weeks
after AOM injection and when tumors had developed in some animals of each group. Total RNA,
purified from non-tumor tissue within the proximal half of each colon, was used to prepare
biotinylated probes, which were hybridized to Affymetrix RG_U34A rat microarrays containing
probes sets for 8799 rat genes. Microarray data were analyzed using DMT (Affymetrix), SAM
(Stanford) and pair-wise comparisons. Differentially expressed genes (SPI and/or WPH vs. CAS)
were found. We identified 31 induced and 49 repressed genes in the proximal colons of the SPI-
fed group and 44 induced and 119 repressed genes in the proximal colons of the WPH-fed group,
relative to CAS. Hierarchical clustering identified the co-induction or co-repression of multiple
genes by SPI and WPH. The differential expression of I-FABP (2.92-, 3.97-fold down-regulated in
SPI and WPH fed rats; P = 0.023, P = 0.01, respectively), cyclin D1 (1.61-, 2.42-fold down-regulated
in SPI and WPH fed rats; P = 0.033, P = 0.001, respectively), and the c-neu proto-oncogene (2.46-
, 4.10-fold down-regulated in SPI and WPH fed rats; P < 0.001, P < 0.001, respectively) mRNAs
were confirmed by real-time quantitative RT-PCR. SPI and WPH affected colonic neuro-endocrine
gene expression: peptide YY (PYY) and glucagon mRNAs were down-regulated in WPH fed rats,
whereas somatostatin mRNA and corresponding circulating protein levels, were enhanced by SPI
and WPH.
Conclusions: The identification of transcripts co- or differentially-regulated by SPI and WPH diets
suggests common as well as unique anti-tumorigenesis mechanisms of action which may involve
growth factor, neuroendocrine and immune system genes. SPI and WPH induction of somatostatin,
a known anti-proliferative agent for colon cancer cells, would inhibit tumorigenesis.
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Background
Colorectal cancer (CRC) is the third most common cancer
and the third leading cause of cancer-related mortality in
the U.S. [1,2]. Estimated new cases of colon cancer were
79,650 for men and 73,530 for women in 2004 [1];
approximately $6.3 billion is spent in the United States
each year on treatment of CRC [2]. Accumulating evi-
dence suggests that diet is an important environmental
factor in the etiology of CRC. High consumption of red
meats, animal fats, chocolate, alcohol and refined cereals
are linked to higher incidence of these cancers in Western
societies [3-5], whereas protective effects of fruits, vegeta-
bles and whole grains have been suggested [5].
Soy foods and soybean constituents have received consid-
erable attention for their potential role in reducing cancer
risk [6,7]. Our laboratories reported the protective effects
of lifetime ingestion of soy protein isolate (SPI) on
azoxymethane (AOM)-induced colon cancer in rats [8].
Similarly, the effect of whey protein hydrolysate (WPH) in
the diet to reduce colon tumor incidence has been
reported by us and others [9-11]. Several hypotheses have
been proposed to account for soy and whey protein-
induced anti-tumorigenesis. For example, soy isoflavones
have been proposed to play a key role in soy's anti-cancer
functions [12]. Yanagihara et al., among others, reported
that genistein inhibits colon cancer cell proliferation and
stimulates apoptosis in vitro [13-15]. However, subcuta-
neous administration of genistein to mice did not confirm
these in vitro effects [16]. Holly et al. reported that soy
sphingolipids inhibit colonic cell proliferation, and sug-
gested that this may partially account for its anticancer
benefits [17]. Other reports indicate that soy diets inhibit
tumorigenesis by regulating the synthesis or activities of
specific proteins. For example, Rowlands et al. reported
that dietary soy and whey proteins down-regulate expres-
sion of liver and mammary gland phase I enzymes
involved in carcinogen activation [18]. Elevated activities
of phase II detoxification enzymes were reported in soy-
fed rats [19,20]. Such dietary effects may result in lower
tissue concentrations of activated carcinogen. The antican-
cer properties of whey proteins have been ascribed to their
ability to elevate cellular levels of the antioxidant glutath-
ione [21,22]. Moreover, the whey protein, α-lactalbumin,
inhibits proliferation of mammary epithelial cells in vitro
[11]. The anticancer properties of whey may also relate to
its immune system-enhancing actions [23].
Despite extensive research, there is no consensus for anti-
cancer mechanism(s) of soy and whey, which will
undoubtedly involve multiple interrelated processes,
pathways and many components. Many of the same
molecular and biochemical changes underlying human
colon cancer are observed in the azoxymethane (AOM)-
induced rat colon cancer model [24]. Moreover, previous
studies suggest a different molecular etiology for tumors
of the proximal and distal colon in this model and in
human colon [24,25]. Differential dietary effects on prox-
imal vs. distal colon DNA damage were noted [26] and
Westernization of the human diet is thought to have
favored a shift of tumors from distal to more proximal
locations [27]. Thus, region-specific localization of dietary
effects on colon tumorigenesis is an important factor to
consider in any molecular analysis of CRC. Here, we use
Affymetrix high-density oligonucleotide microarrays to
determine the expression profiles of non-tumor (i.e., nor-
mal) tissue in proximal colons (PC) of rats, subjected to
lifetime diets containing casein (CAS, control diet), soy
protein isolate (SPI), or whey protein hydrolysate (WPH)
and which were administered AOM to induce tumors. We
hypothesized that genes whose expression contributes to
anti-tumorigenesis would be regulated in parallel by SPI
and WPH; in addition, changes unique to each diet might
also be apparent.
Results
Validation of the microarray approach
Quality control steps ensured that the RNA used for
microarray and real-time RT-PCR analysis was of high
quality. These steps included evaluation of the RNA with
the RNA 6000 Nano Assay and assessment of the cRNA
hybridization to GeneChips by comparison of data
obtained for probe sets representative of 5' and 3' ends of
control genes. All RNA samples had an A260/280 absorb-
ance ratio between 1.9 and 2.1. The ratio of 28S to 18S
rRNA was very close to 2 on RNA electropherograms, and
signal ratios below 3 were noted for 3' vs. 5' probe sets for
β-actin and glyceraldehyde-3-phosphate dehydrogenase
(per Affymetrix user guidelines) after hybridization.
Total false change rates (TFC) were determined following
Affymetrix-recommended guidelines [28], except that the
inter-chip comparisons used cRNA targets made in paral-
lel starting from the same RNA pool. Inter-chip variability,
measured as TFC%, was 0.25% – 0.6% and well below the
suggested 2% cutoff (Table 1). These values confirmed the
fidelity and reproducibility of the microarray procedures
Table 1: Inter-chip variability
Diet group Number of arrays TFC (%)*
CAS 3 0.252 ± 0.138
WPH 3 0.369 ± 0.025
SPI 3 0.570 ± 0.165
*TFC (Total false change) = false change rate (decreased category) + 
false change rate (increased category), as described in ref. 28; TFC 
reported as mean ± SEM, TFC should be no more than 2% 
(Affymetrix).Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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used. Unsupervised nearest-neighbor hierarchical cluster-
ing identified differences in proximal colon gene expres-
sion profiles of CAS, SPI and WPH groups (Figs. 1 and 2),
indicating that the type of dietary protein has a major
effect on gene expression in normal proximal colon tissue
of AOM-treated rats. Interestingly, the overall gene expres-
sion profiles for SPI and WPH groups were more similar
to each other than each was to the CAS group (Fig. 1A).
Differentially expressed genes
Multiple filtering criteria were applied to the microarray
data set so as to identify differentially expressed colon
transcripts in rats fed SPI, WPH or CAS; results are
reported only for transcripts that passed all three analyti-
cal filters used: DMT t-test, SAM and pair-wise comparison
survival methods. Among the 8799 genes and ESTs exam-
ined with the rat U34A array, we identified 31 induced
and 49 repressed genes in proximal colons of SPI-fed rats,
whereas 44 induced and 119 repressed genes were
detected in WPH-fed rats (Tables 2, 3, 4, 5). Interestingly,
Hierarchical clustering of proximal colon gene expression  profiles Figure 1
Hierarchical clustering of proximal colon gene expression 
profiles. A. Clustering of nine PC global gene expression 
profiles (8799 genes); n = 3 profiles each for CAS, SPI and 
WPH. Each cell represents the expression level of an individ-
ual gene in each sample (green = low expression, black = 
middle expression, red = high expression). The dendrogram 
reflects the extent of relatedness of different profiles; the 
shorter branch-point of the SPI and WPH trees indicates the 
greater similarity between these profiles. B. Clustering of 18 
global comparative expression profiles including 9 of SPI vs. 
CAS and 9 of WPH vs. CAS profiles. Each row in the heat 
map represents the relative expression level of a given gene 
across all comparisons (red = up regulated, black = 
unchanged, green = down regulated).
A Hierarchical clustering of expression  profiles
CAS1  CAS2 CAS3  SPI3   SPI1   SPI2  WPH1 WPH3 WPH2 
B Hierarchical clustering of comparative analysis profiles
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Hierarchical clustering of 211 differentially expressed genes  in either SPI or WPH Figure 2
Hierarchical clustering of 211 differentially expressed genes 
in either SPI or WPH. The differential expression data are 
taken only from the pairwise comparison analysis, with CAS 
profiles used as baseline. Each cell in the heat map represents 
the relative expression level of a given gene in an individual 
comparison analysis (red = up regulated, black = unchanged, 
green = down regulated). The dendrogram reflects the relat-
edness of different profiles.
Hierarchical clustering of regulated gene  profiles
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Table 2: Down-regulated genes in rats fed with WPH diet*
Category and Gene Name Probe Set GB Accession No. Fold Change P value
Cell adhesion
Embigin AJ009698 -6.57 0
Cadherin 17 L46874 -4.8 0.036
Cadherin X78997 -3.36 0.004
Protein tyrosine phosphatase M60103 -2.64 0.004
Cytokeratin-8 S76054 -2.71 0
Trans-Golgi network integral membrane protein TGN38 X53565 -4.92 0.012
Tumor-associated calcium signal transducer 1 AJ001044 -9.37 0.001
Claudin-3 AJ011656 -7.55 0.02
Claudin-9 AJ011811 -5.12 0
Cell cycle/growth control
Mapk6 M64301 -2.61 0.003
Epithelial membrane protein 1 Z54212 -4.67 0.015
Glucagon K02813 -7.73 0.005
Peptide tyrosine-tyrosine (YY) M17523 -4.56 0.001
Src related tyrosine kinase U09583 -3.31 0.033
FGF receptor activating protein U57715 -4.25 0.002
Cyclin D1 D14014 -1.97 0.001
Neu oncogene X03362 -2.61 0.017
Defense/immunity protein
Seminal vesicle secretion protein iv J00791 -5.35 0.001
Putative cell surface antigen U89744 -5.22 0.008
Decay accelerating factor GPI AF039583 -6.12 0
Beta defensin-1 AF093536 -26.78 0.001
Detoxification/antioxidation
Glutathione S-transferase J02810 -5.17 0
Glutathione S-transferase Yb X04229 -9.33 0
J03914 -2.43 0.002
Glutathione S-transferase, alpha 1 K01932 -3.07 0.002
Glutathione transferase, subunit 8 X62660 -6.42 0.001
Glutathione S-transferase Yc1 S72505 -3.69 0.004
Glutathione S-transferase Yc2 S72506 -21.38 0.008
N-acetyltransferase 1 U01348 -4.64 0.003
Cytochrome P450CMF1b J02869 -8.23 0.001
Cytochrome P450 4F4 U39206 -6.43 0.004
Cytochrome P450 monooxygenase U39943 -2.82 0.011
Cytochrome P450 pseudogene U40004 -2.87 0
Cytochrome P450 3A9 U46118 -6.91 0
Cytochrome P450IVF M94548 -5.78 0.002
Cytochrome P450, subfamily 51 U17697 -2.07 0.005
Alcohol dehydrogenase M15327 -2.06 0.025
Aldehyde dehydrogenase M23995 -10.56 0.035
AF001898 -2.72 0.004
D-amino-acid oxidase AB003400 -13.69 0
3-methylcholanthrene-inducible UDP-
glucuronosyltransferase
S56937 -9 0
UDP-glucuronosyltransferase D38062 -3.17 0.005
D38065 -3.29 0.002
UDP glycosyltransferase 1 D83796 -6.87 0
J02612 -6.58 0
J05132 -4.03 0
Metabolism
Meprin 1 alpha S43408 -3.82 0.014
Brain serine protease bsp1 AJ005641 -4.42 0.007
Cystathionine gamma-lyase D17370 -3.05 0.002
Cathepsin S L03201 -2.62 0
Meprin beta-subunit M88601 -5 0.004
Disintegrin and metalloprotease domain 7 X66140 -11.91 0
Fucosyltransferase 1 AB006137 -4.96 0.001
Fucosyltransferase 2 AB006138 -7.97 0.017Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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UDP-glucose:ceramide glycosyltransferase AF047707 -2.86 0.007
Type II Hexokinase D26393 -2.7 0.001
Hexokinase II S56464 -4.45 0.007
CDP-diacylglycerol synthase AB009999 -4.66 0
Carboxylesterase precursor AB010635 -5.29 0.002
Fatty acid Coenzyme A ligase AB012933 -2.5 0.041
3beta-HSD L17138 -3.27 0
11-beta-hydroxylsteroid dehydrogenase type 2 U22424 -3 0.001
Peroxiredoxin 6 AF014009 -3.55 0.01
Platelet phospholipase A2 X51529 -3.25 0.001
Ligand binding/carrier
Carnitine transporter AB017260 -3.95 0.005
Chloride channel (ClC-2) AF005720 -5.69 0.002
Putative potassium channel AF022819 -4.84 0
Mitochondrial dicarboxylate carrier AJ223355 -3.55 0.009
Aquaporin 3 D17695 -7.83 0
Na_H_Exchanger L11236 -9.81 0.003
Angiotensin/vasopressin receptor (AII/AVP) M85183 -3.3 0.002
H+, K+-ATPase M90398 -13.87 0
Intestinal fatty acid binding protein K01180 -7.29 0.001
Apolipoprotein A-I precursor M00001 -3.45 0.023
Apolipoprotein A-I J02597 -2.47 0.003
Sodium-hydrogen exchange protein-isoform 3 M85300 -7.36 0.004
Liver fatty acid binding protein V01235 -2.62 0
Sodium transporter X59677 -3.8 0
Cation transporter X78855 -3.62 0.003
ATP-binding cassette AB010467 -3.89 0.004
Methionine adenosyltransferase II, alpha J05571 -2.91 0.007
Phenylalanine hydroxylase M12337 -7.43 0
Carbonic anhydrase IV S68245 -4.28 0.011
Signal transduction
B7 antigen X76697 -170.95 0.002
CD24 antigen U49062 -3.08 0
Chemokine CX3C AF030358 -5.04 0.011
Itmap1 AF022147 -7.5 0.001
HCNP E05646 -2.5 0.001
Brain glucose-transporter protein M13979 -2.97 0.019
Protein kinase C delta M18330 -2.48 0.002
Guanylate cyclase 2C M55636 -4.58 0.003
A2b-adenosine receptor M91466 -2.8 0.04
Guanylate cyclase activator 2A M95493 -4.18 0.005
Phospholipase C beta-3 M99567 -2.57 0.018
Tm4sf3 Y13275 -3.33 0
Phospholipase D AB000778 -2.71 0.009
BEM-2 D45413 -6.41 0.015
Sgk L01624 -3.93 0
Stress response/apoptosis
Prostaglandin D synthetase J04488 -43.11 0.009
GTP cyclohydrolase I M58364 -3.26 0.014
Structure proteins
Chromogranin B (Chgb) AF019974 -2.56 0.005
Intestinal mucin M76740 -5.09 0.002
Muc3 U76551 -11.07 0.006
Mucin-like protein M81920 -11.97 0.001
Myosin 5B U60416 -3.94 0
Keratin 18 X81448 -3.23 0.004
Keratin 19 X81449 -2.69 0.001
ZG-16p protein Z30584 -4.43 0.002
Plasmolipin Z49858 -7.2 0
Cytokeratin 21 M63665 -4.96 0
Syndecan S61865 -3.3 0.006
Claudin 3 M74067 -6.68 0.01
Table 2: Down-regulated genes in rats fed with WPH diet* (Continued)Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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more down- than up-regulated genes were noted for both
SPI and WPH. Additionally, 37 genes were co-repressed,
whereas only two were co-induced by SPI and WPH
(Table 6). More than 90% of identified genes in WPH and
SPI animals showed the same direction of change relative
to CAS. This is visually apparent in the hierarchical clus-
tering output (Fig. 2).
Gene expression: effects of WPH
As based on Gene Ontology (GO) annotations, the 44 up-
regulated and 119 down-regulated genes of the WPH
group belong to multiple functional categories including
cell adhesion (n = 10), cell cycle and growth control (n =
10), detoxification (n = 17), defense and immunity (n =
7), signal transduction (n = 29), transcriptional regulation
(n = 6), metabolism (n = 19), ligands and carriers (n =
27), cell death (n = 3), structural proteins (n = 16), and
others (Tables 2 &3). The fold change for up-regulated
genes ranged between 2.1 [small nuclear ribonucleoparti-
cle-associated protein (snRNP)] to 4.7 (argininosuccinate
synthetase), whereas down-regulated genes exhibited fold
changes between 2.0 (cyclin D1) and 171 (CD52
antigen).
Lifetime ingestion of WPH affected the expression of
xenobiotic metabolism-related enzymes including several
of the cytochrome P450s and glutathione S-transferases,
alcohol dehydrogenase (ADH), and UDP-glucuronosyl-
transferase. Cytochrome P450 enzymes and ADH are con-
sidered to play key roles in activation of the proximate
carcinogen from AOM [29]. Down-regulation of expres-
sion of Phase I detoxification enzymes by WPH might
therefore diminish AOM-induced DNA adducts and
genomic instability. Consistent with results from a study
in which whey proteins inhibited cell proliferation in vitro
[11], lifetime feeding of WPH was associated with changes
in expression of genes involved in cell cycle control and
proliferation; cyclin D1, neu oncogene, mapk6, glucagon,
and peptide YY (PYY) genes were down-regulated,
whereas the expression of somatostatin, a growth-inhibi-
tory peptide was induced. WPH altered expression of
genes involved in cellular defense. Induced genes
included Ig gamma heavy chain, adipsin, and T-cell recep-
tor beta chain, whereas expression of the antibacterial
peptide beta defensin-1 and seminal vesicle secretion pro-
tein IV (SVS IV) were down-regulated. About 20% of
WPH-affected genes are involved in cell signaling; these
include guanylate cyclase 2C, protein kinase C delta, and
synapsin. Additionally, genes encoding ligands or mem-
brane channels [i.e., chloride channel, intestinal fatty acid
binding protein (I-FABP), apoliprotein A-I (Apo-AI), Na+,
K+-ATPase, and sodium transporter] were down-regulated
by WPH, whereas calretinin and retinol binding protein
(RBP) levels were increased.
Gene expression: effects of SPI
Colon genes, whose mRNA expression was affected by
ingestion of SPI, fell into multiple functional categories
including cell adhesion (n = 4), cell cycle and growth con-
trol (n = 6), detoxification (n = 18), defense and immu-
nity (n = 6), signal transduction (n = 4), transcriptional
regulation (n = 1), metabolism (n = 8), ligands and carrier
proteins (n = 17), cell death proteins (n = 5), and struc-
tural proteins (n = 3) (Tables 4 &5).
Relative abundance of numerous transcripts was changed
in the same direction by WPH and SPI (Fig. 2). However,
some exceptions were noted. For example, mRNA encod-
ing Apo-AI was down-regulated by WPH, but elevated by
SPI. Apo-AI is the major determinant of the capacity of
HDL particles to promote cholesterol efflux and this pro-
tein is associated with the inhibition of atherosclerosis
[30]. However, the impact of differential response of Apo-
AI to WPH and SPI on anti-tumorigenesis is unknown.
Transcription factor/regulator
Hepatocyte nuclear factor 3 gamma AB017044 -6.96 0
Apolipoprotein B mRNA editing protein L07114 -2.34 0
DNA-binding inhibitor L23148 -4.1 0.01
Kruppel-like factor 4 (gut) L26292 -3.08 0.017
Others
Prolactin receptor M74152 -3.26 0.014
LOC286964 U89280 -2.96 0.003
Ckmt1 X59737mRNA -2.65 0.025
Arginase II U90887 -23.69 0
Deleted in malignant brain tumors 1 U32681 -3.47 0.002
3' end GAA-triplet repeat L13025 -2.73 0.001
Polymeric immunoglobulin receptor L13235 -2.93 0.004
*Changes in gene expression were determined by t-test (DMT), comparative analysis (MAS 5.0), and SAM (Stanford). Gene expression profiles 
from CAS animals were used as control. P value and fold change are based on DMT analysis; whereas final genes listed met all of the analytical 
criteria as described in Methods.
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Table 3: Up-regulated genes in rats fed with WPH diet*
Category and Gene Name Probe Set GB Accession 
No.
Fold Change P value
Cell adhesion
Fibronectin X05834 2.3 0
EGF-containing fibulin-like extracellular matrix protein 1 D89730 2.17 0.004
Cell cycle/growth control
Somatostatin M25890 2.72 0.001
Somatostatin-14 K02248 3.87 0.009
APEG-1 U57097 3.24 0.002
Defense/immunity protein
IgG gamma heavy chain M28670 2.21 0.009
T-cell receptor beta chain X14319 2.14 0
Adipsin M92059 3.21 0
Ligand binding/carrier
Angiotensin receptor M86912 2.75 0.017
Calretinin X66974 2.52 0.005
Purkinje cell protein 4 M24852 3.06 0.001
Secretogranin III U02983 2.77 0.005
Secretogranin II M93669 2.84 0.001
Aquaporin 1 X67948 3.4 0.008
Cacna2d1 M86621 2.84 0
Retinol-binding protein M10934 2.17 0.018
Metabolism
Lipoprotein lipase L03294 2.72 0
Ubiquitin carboxyl-terminal hydrolase D10699 3 0.003
Signal transduction
Thy-1 protein X02002 2.89 0.002
CD3 gamma-chain S79711 3.28 0.002
Synapsin M27925 3.94 0.001
Alpha-actinin-2 associated LIM protein AF002281 2.74 0.009
RESP18 L25633 2.74 0.033
T3 delta protein X53430 2.75 0.003
Protein phosphatase inhibitor-1 J05592t 2.6 0.009
CART protein U10071 2.16 0.001
Neuroendrocrine protein M63901 3.7 0.006
Protein kinase C-binding protein Zeta1 U63740 3.14 0.003
cannabinoid receptor 1 X55812 2.17 0.002
Guanylyl cyclase A J05677 3.18 0.007
Tachykinin 1 X56306 2.36 0.036
Protein tyrosine phosphatase L19180 2.47 0.041
Argininosuccinate synthetase X12459 4.69 0.004
Stress response/apoptosis
Small inducible cytokine Y08358 3.35 0.029
Structure proteins
Fast myosin alkali light chain L00088 4.52 0.03
Light molecular-weight neurofilament AF031880 2.41 0
Neurofilament protein middle Z12152 2.97 0.006
Alpha-tubulin V01227 2.25 0
Peripherin AF031878 2.82 0.007
Transcription factor/regulator
snRNP M29293 2.11 0.004
snRNP-associated polypeptide X73411 3.33 0.002
Others
C1-13 gene product X52817 3.17 0
ND5, ND6 S46798 2.31 0.015
Sensory neuron synuclein X86789 2.84 0
*Changes in gene expression were determined by t-test (DMT), comparative analysis (MAS 5.0), and SAM (Stanford). Gene expression profiles 
from CAS animals were used as control. P value and fold change are based on the DMT analysis; whereas listed genes met all of the analytical 
criteria as described in Methods.Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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Table 4: Down-regulated genes in rats fed with SPI diet*
Category and Gene Name Probe Set GB Accession 
No.
Fold Change P value
Cell adhesion
Embigin AJ009698 -5.13 0.001
Cell Cycle/growth control
FGF receptor activating protein 1 U57715 -5.59 0.002
BEST5 protein Y07704 -2.37 0.003
Peptide tyrosine-tyrosine (YY) M17523 -3.91 0.002
Glucagon gene K02813 -6.58 0.002
Epithelial membrane protein-1 Z54212 -3.47 0.017
Neu oncogene X03362 -1.58 0.05
Defense/immunity protein
Beta defensin-1 AF068860 -42.16 0.001
AF093536 -10.2 0
Detoxification/antioxidation
Glutathione S-transferase J02810 -7.14 0
Glutathione S-transferase Yb X04229 -11.71 0.001
Glutathione S-transferase, alpha 1 K01932 -4.18 0.004
Glutathione S-transferase Yc1 S72505 -5.23 0.001
Glutathione S-transferase Yc2 S72506 -5.27 0.012
S82820 -3.45 0.006
Cytochrome P450 4F4 (CYP4F4) U39206 -6.52 0.002
Cytochrome P450CMF1b J02869 -4.12 0.002
Cytochrome P450 (CYP4F1) M94548 -2.88 0.002
1-Cys peroxiredoxin Y17295 -2.55 0.002
Metallothionein M11794 -2.92 0.006
D-amino-acid oxidase AB003400 -5.42 0
Peroxiredoxin 6 AF014009 -3.07 0.008
Phenylalanine hydroxylase M12337 -10.99 0.001
Metabolism
Dipeptidase L07315 -3.08 0.001
Meprin beta-subunit M88601 -3.27 0.001
Disintegrin and metalloprotease domain 7 X66140 -14.03 0
Ligand binding/carrier
Carnitine transporter AB017260 -3.81 0.003
Chloride channel (ClC-2) AF005720 -3.26 0.001
Putative potassium channel AF022819 -2.69 0.001
Mitochondrial dicarboxylate carrier AJ223355 -2.54 0.01
Aquaporin 3 D17695 -4.13 0
Intestinal fatty acid binding protein K01180 -4.43 0.005
Na_H_Exchanger L11236 -4.47 0.002
H+, K+-ATPase M90398 -2.52 0.001
Carbonic anhydrase IV S68245 -4.28 0.005
Sodium transporter X59677 -3.4 0
Phosphatidylethanolamine binding protein X75253 -2.69 0
Signal transduction
B7 antigen X76697 -170.95 0.002
HCNP E05646 -3.38 0
Itmap1 AF022147 -7.97 0.005
Guanylate cyclase activator 2A M95493 -3.28 0.006
Sgk L01624 -2.76 0
Stress response/apoptosis
Prostaglandin D synthetase J04488 -45.8 0.01
Structure proteins
Muc3 U76551 -3.56 0.01
Intestinal mucin M76740 -3.31 0.006Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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Confirmation of differential gene expression
We performed quantitative real-time RT-PCR on selected
genes to confirm the microarray results. Based upon
known associations with cell proliferation or
differentiation, 14 genes were chosen for further study.
Included in this group was BTEB2; this gene was not
present on the microarrays but was included in RT-PCR
analysis due to its significant expression in intestine and
involvement in cell proliferation [see discussion]. As
shown in Figure 3, eight genes were confirmed to be dif-
ferentially expressed: these included the gastrointestinal
hormone genes PYY (12.9-fold down-regulated in WPH
fed rats; P = 0.004), glucagon (17.8-fold down-regulated
in WPH fed rats; P = 0.005), and somatostatin (3.92-,
2.65-fold up-regulated in SPI and WPH fed rats; P = 0.05,
P = 0.025, respectively); cyclin D1 (1.6-, 2.4-fold down-
regulated in SPI and WPH fed rats; P = 0.033, P = 0.001,
respectively); BTEB2 (1.9-, 6.7-fold down-regulated in SPI
and WPH fed rats; P = 0.024, P < 0.001, respectively); c-
neu proto-oncogene (2.5-, 4.1-fold down-regulated in SPI
and WPH fed rats; P < 0.001, P < 0.001, respectively); the
colonocyte differentiation marker I-FABP (2.9-, 4.0-fold
down-regulated in SPI and WPH fed rats; P = 0.023, P =
0.01, respectively); and the mucin, MUC3 (2.78-, 4.05-
fold down-regulated in SPI and WPH fed rats; P < 0.001,
P < 0.001, respectively). Differential expression of five
other genes was not confirmed statistically, due to indi-
vidual animal variation in the transcript levels; however,
the mean-fold changes for mRNA abundance were greater
than two and in agreement with the corresponding micro-
array results for these genes. Only one of the selected
genes – retinol binding protein (RBP), failed to exhibit
greater than a 2-fold change (in the predicted direction) at
the mRNA level by real-time RT-PCR.
Serum somatostatin (Sst)
As shown in Fig. 4, circulating Sst concentration was sig-
nificantly higher in rats fed WPH and SPI. Colonic Sst pro-
tein content in colon homogenates was below the limit of
detection of the assay used (data not shown).
Discussion
The type of dietary protein(s) can markedly affect the
onset and/or progression of CRC [31]. Epidemiological
and animal studies have found that dietary soy and whey
proteins decrease the incidence of certain tumors, includ-
ing those of the colon and rectum [6,7,32-35]. Using the
AOM-treated male Sprague Dawley rat model, we previ-
ously found that lifetime feeding of SPI led to a ~ 76%
lower incidence of AOM-induced colon tumors compared
to rats lifetime-fed CAS [8]. Additionally, in the same
studies, a ~ 46% lower incidence of colon tumors was
found in WPH-fed compared to CAS-fed rats [9]. The
molecular mechanism(s) by which these dietary proteins
reduce the incidence of chemically-induced colon tumors
is unclear, although several mechanisms and putative bio-
active factors have been proposed [11-24]. The present
study has now identified genes that are differentially
expressed as a function of these diets and which serve to
highlight potential pathways for dietary protection from
carcinogenesis.
The ability to simultaneously analyze a large number of
different mRNAs makes microarrays very appealing for
identifying genes and gene families whose expression is
altered by diet [36,37]. We focused on the 'normal' colon
tissue since we are interested in genes that are
differentially regulated by diet and which act in anti-onco-
genic fashion in pre-cancerous tissues. We limited our
analysis to the proximal colon since several studies have
suggested that the molecular etiology of proximal and dis-
tal colon tumors differs [25,26] and proximal colon
tumors have become more prevalent with Westernization
of the diet and aging of the population [27]. We chose to
include colonic smooth muscle with the mucosa since: a)
the former tissue layer interacts with the latter to influence
its growth and function, and b) we could monitor all
colonic genes affected by diet. However, one potential
caveat to this strategy is the 'dilution' effect that may have
been imposed on the more rare mucosal transcripts.
Another caveat is that no information is obtained regard-
ing where the differentially expressed transcripts occur. In
Mucin-like protein M81920 -3 0
Plasmolipin Z49858 -2.92 0.003
Transcription factor/regulator
Testis specific X-linked gene X99797 -6.91 0.003
Others
Arginase II U90887 -3.22 0
3-phosphoglycerate dehydrogenase X97772 -4.15 0.017
Aldehyde dehydrogenase family 1 AF001898 -3.93 0.004
*Changes in gene expression were determined by t-test (DMT), comparative analysis (MAS 5.0), and SAM (Stanford). Gene expression profiles 
from CAS animals were used as control. P value and fold-change are based on the DMT analysis; whereas genes listed above met all of the analytical 
criteria as described in Methods.
Table 4: Down-regulated genes in rats fed with SPI diet* (Continued)Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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this regard, however, we have confirmed by immuno-his-
tochemistry that I-FABP is expressed predominantly in the
inter-cryptal surface epithelium of colons from AOM-
treated rats (Fig. 5). Our study used a sample size of three
(per diet group) which balanced the costs for the experi-
mental reagents with the minimum number required for
statistical analysis. The quantitative PCR analyses
provided confirmation that the filtering strategies used
yielded bona-fide differentially expressed transcripts.
Only two transcripts were induced by both SPI and WPH;
whereas 37 transcripts were repressed by both SPI and
WPH. This suggests that the cancer-protective actions of
the two diets are generally associated with repression of
colonic genes that facilitate tumorigenesis. An alternative
explanation is that CAS induces genes that facilitate colon
cancer development when compared to SPI and WPH. It
is also likely that SPI and WPH diets act in unique ways to
inhibit tumorigenesis. Irregardless, our results indicate
that the nature of the dietary protein can profoundly affect
Table 5: Up-regulated genes in rats fed with SPI diet*
Category and Gene Name Probe Set GB Accession 
No.
Fold Change P value
Cell adhesion
Collagen alpha1 type I Z78279 2.49 0
Secreted phosphoprotein 1 M14656 111.39 0.006
Matrix metalloproteinase 13 M60616 24.34 0.002
Regenerating islet M62930 193.08 0.011
Defense/immunity protein
Ig gamma-2a chain L22654 115.17 0.001
Ig gamma heavy chain M28670 3.22 0
Ig germline kappa-chain C-region M18528 2.48 0.038
Ig light-chain U39609 2.63 0.021
Fc-gamma M32062 4.72 0.017
Detoxification
Glutathione S-transferase 1 J03752 2.86 0
Glutathione-S-transferase,alpha type2 K00136 2.56 0.009
UDP glucuronosyltransferase D38066 2.83 0.014
Metabolism
Matrix metalloproteinase 7 L24374 3.63 0.02
lysozyme rc_AA892775 2.77 0
Matrix metalloproteinase 12 X98517 11.8 0.013
Mitochondrial carbamyl phosphate synthetase I M12335 59.25 0.001
Aldolase B, exon 9 X02291 8.7 0.01
Aldolase B, exon 2 X02284 2.71 0.001
Signal transduction
MHC class II antigen RT1.B-1 beta-chain X56596 2.55 0.001
CD3 gamma-chain S79711 4.51 0.001
Ligand binding/carrier
Intracellular calcium-binding protein L18948 28.29 0.014
Retinol binding protein II M13949 5.11 0.001
Apolipoprotein B M27440 6.47 0.024
Apolipoprotein A-I J02597 2.49 0.004
Iron ion transporter AF008439 18.78 0.008
Stress response/apoptosis
Heme oxygenase J02722 9.66 0.002
JE product X17053 3.52 0.001
Pancreatitis-associated protein M98049 68.39 0.004
Pancreatitis associated protein III L20869 15.35 0
Reg protein E01983 30.25 0.001
Others
Histamine N-tele-methyltransferase S82579 6.17 0.04
*Changes in gene expression were determined by t-test (DMT), comparative analysis (MAS 5.0), and SAM (Stanford). Gene expression profiles 
from CAS animals were used as control. P value and fold-change are based on the DMT analysis; whereas final listed genes met all of the analytical 
criteria as described in the Methods.Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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colon gene expression profiles. Thus, gene expression pro-
filing studies of colons should account for potential con-
founding effects of diet.
Dietary factors in SPI or WPH inhibit cell proliferation
and induce apoptosis among other biological actions
[11,13]. In the present study, we identified cyclin D1 gene
and the neu proto-oncogene as being repressed in proxi-
mal colon by SPI and WPH. Cyclin D1 is a key regulator
of cell cycle progression [38], and a target of β-catenin, a
protein whose abnormal accumulation in the nucleus is
strongly linked to the development of multiple tumor
types, including those of the colon [39]. Aberrantly
increased expression of cyclin D1 in colon epithelial cells
contributes to their abnormal proliferation and tumori-
genicity [40,41]. Similarly, the oncogenic and cellular
growth-promoting activities of the HER-2/neu proto-
oncogene are well known [42]. HER-2/neu, a tyrosine
kinase receptor for neu-differentiation factor, is expressed
in normal colonic epithelium and is up-regulated in ade-
Table 6: Genes co-regulated with WPH and SPI diet*
Category and Gene Name Probe Set GB Accession No. Fold Change in WPH P value Fold Change in SPI P value
Down-regulated genes
Embigin AJ009698 -6.57 0 -5.13 0.001
Epithelial membrane protein 1 Z54212 -4.67 0.015 -3.47 0.017
Glucagon K02813 -7.73 0.005 -6.58 0.002
Peptide tyrosine-tyrosine (YY) M17523 -4.56 0.001 -3.91 0.002
FGF receptor activating protein U57715 -4.25 0.002 -5.59 0.002
Neu oncogene X03362 -2.61 0.017 -1.58 0.05
CD52 antigen X76697 -170.95 0.002 -170.95 0.002
Beta defensin-1 AF068860 -54.48 0.001 -42.16 0.001
Glutathione S-transferase J02810 -5.17 0 -7.14 0
Glutathione S-transferase Yb X04229 -9.33 0 -11.71 0.001
Glutathione S-transferase, alpha 1 K01932 -3.07 0.002 -4.18 0.004
Glutathione S-transferase Yc1 S72505 -3.69 0.004 -5.23 0.001
Glutathione S-transferase Yc2 S72506 -21.38 0.008 -5.27 0.012
Cytochrome P450CMF1b J02869 -8.23 0.001 -4.12 0.002
Cytochrome P450 4F4 U39206 -6.43 0.004 -6.52 0.002
Cytochrome P450IVF M94548 -5.78 0.002 -2.88 0.002
D-amino-acid oxidase AB003400 -13.69 0 -5.42 0
Meprin beta-subunit M88601 -5 0.004 -3.27 0.001
Disintegrin and metalloprotease domain 7 X66140 -11.91 0 -14.03 0
Carnitine transporter AB017260 -3.95 0.005 -3.81 0.003
Chloride channel (ClC-2) AF005720 -5.69 0.002 -3.26 0.001
Putative potassium channel AF022819 -4.84 0 -2.69 0.001
Mitochondrial dicarboxylate carrier AJ223355 -3.55 0.009 -2.54 0.01
Aquaporin 3 D17695 -7.83 0 -4.13 0
Na_H_Exchanger L11236 -9.81 0.003 -4.47 0.002
H+, K+-ATPase M90398 -13.87 0 -2.52 0.001
Fatty acid binding protein 1 K01180 -7.29 0.001 -4.43 0.005
Sodium transporter X59677 -3.8 0 -3.4 0
Carbonic anhydrase IV S68245 -4.28 0.011 -4.28 0.005
Itmap1 AF022147 -7.5 0.001 -7.97 0.005
HCNP E05646 -2.5 0.001 -3.38 0
Guanylate cyclase activator 2A M95493 -4.18 0.005 -3.28 0.006
Sgk L01624 -3.93 0 -2.76 0
Prostaglandin D synthetase J04488 -43.11 0.009 -45.8 0.01
Mucin 3 M76740 -5.09 0.002 -3.31 0.006
Mucin-like protein M81920 -11.97 0.001 -3 0
Plasmolipin Z49858 -7.2 0 -2.92 0.003
Up-regulated genes
Ig gamma heavy chain M28670 2.21 0.009 3.22 0
CD3 gamma-chain S79711 3.28 0.002 4.51 0.001
*Changes in gene expression were determined by t-test (DMT), comparative analysis (MAS 5.0), and SAM (Stanford). Gene expression profiles from 
CAS animals were used as control. P value and fold change are based on the DMT analysis; whereas final listed genes met all of the analytical criteria 
described in Methods.Molecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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nomatous polyps of the colon [43]. The down regulation
of cyclin D1 and c-neu mRNA abundance by SPI and
WPH may at least partly explain their anti-tumorigenic
properties. Similarly, Krüppel-like transcription factors
have been linked to cell growth and tumorigenesis. BTEB2
(also known as Krüppel-like factor 5, KLF5, or intestinal
KLF) was reported to enhance intestinal epithelia cell col-
ony formation, cyclin D1 transcription, and cell prolifera-
tion [44]. Consistent with our results for cyclin D1,
colonic BTEB2 mRNA expression was down-regulated by
SPI and WPH. Aquaporin 3, a water channel highly
expressed in colonic epithelium, was down-regulated by
SPI and WPH. Aquaporins are thought to be induced early
in colon cancer and to facilitate oncogenesis [45],
therefore, dietary repression of such genes may addition-
ally contribute to anti-tumorigenesis. The results for I-
FABP and MUC3 indicated 3–4 fold decreases in tran-
Quantitative real-time RT-PCR verification of microarray  results Figure 3
Quantitative real-time RT-PCR verification of microarray 
results. RNA used for real-time RT-PCRs was from the same 
animals (n = 7 per diet group) whose RNAs comprised the 
pools for microarray analysis. Values are mean ± SEM and 
were analyzed by one-way ANOVA, *P < 0.05, SPI or WPH 
vs. CAS.
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Immuno-histochemistry for I-FABP in colons from AOM- treated rats Figure 5
Immuno-histochemistry for I-FABP in colons from AOM-
treated rats. Panels A and B are sections from CAS and 
WPH-fed animals, respectively. Arrows point to the strong 
areas of staining for I-FABP in the inter-cryptal surface epi-
thelium (overall intensity of staining is greater for CAS than 
for WPH).
A
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script abundance in proximal colons of rats on SPI or
WPH diets. These particular results are not easily
reconciled with decreased tumorigenesis in SPI and WPH
groups, since both genes are highly expressed in the nor-
mal differentiated colonic epithelium and are likely to be
under-expressed in adenomas and adenocarcinomas [46].
Perhaps, these represent diet-modulated genes that are
not direct participants in anti-tumorigenesis.
Gastrointestinal hormones regulate a myriad of intestinal
functions including motility, absorption, digestion, cell
proliferation and death, and immune response [47]. The
microarray and real-time RT-PCR assays identified induc-
tive effects of SPI and WPH on somatostatin mRNA and
protein abundance. These results implicate this gene
product in autocrine and paracrine mechanisms underly-
ing colon cancer protection by SPI and WPH since
somatostatin is a well-known anti-proliferative agent for
colon tumor cells [48,49]. This hormone is also a negative
regulator of angiogenesis [50]; this is predicted to counter
tumorigenesis. It is possible that the small decrements in
rat growth rates observed with lifetime SPI or WPH diets
[8,9] are a consequence of this increased circulating soma-
tostatin level. We also found decreased abundance of
mRNAs encoding peptide YY (PYY) and glucagon in
colons of WPH-fed rats. PYY gene expression in human
colon tumors is much reduced relative to the adjacent
normal tissue [51]; however, chemically-induced colon
tumors in rats generally exhibit higher overall expression
of PYY due to increased prevalence of PYY-positive cells,
compared to normal mucosa [52,53]. PYY stimulates pro-
liferation of intestinal epithelium [54]; therefore, an inhi-
bition of PYY expression by dietary WPH may contribute
to colon cancer-protective actions. A similar scenario
might apply to colon glucagon gene expression, as this
growth stimulatory peptide for colon cancer cells [55] was
inhibited by WPH at the level of colon mRNA abundance.
Our data highlighted other aspects of diet and colon gene
expression that warrant further study. For example, the B7
antigen (also known as CD52) mRNA was strongly down-
regulated by SPI or WPH. The corresponding protein is
normally expressed at high levels on cell membranes of T
and B lymphocytes and monocytes; infusion with anti-
CD52 antibody leads to systemic depletion of T cells [56].
The lower abundance of this transcript in non-tumor
colon tissue of rats on SPI or WPH diets may reflect fewer
numbers of immune cells in this tissue, as compared to
CAS-fed animals. One possible interpretation of this data
is that the 'normal' tissue of the CAS group has manifested
an immune response, perhaps in response to increased
tumorigenicity relative to SPI or WPH groups. Such an
interpretation raises the prospect of a functional immuno-
editing mechanism [57] occurring in this model of colon
cancer and an indirect effect of diet on lymphocyte popu-
lations (via presence of tumors or tumor precursors) in
the colon. An alternative mechanism is that dietary
protein can directly affect the populations of lymphocytes
resident in the colon, which in turn, may affect tumori-
genesis. A related observation was the enhanced abun-
dance of CD3 gamma chain transcripts in colons of SPI
and WPH animals. The protein encoded by this transcript
helps mediate T cell antigen receptor engagement and sig-
naling [58]; its decreased abundance in colonic T cells of
CAS-fed animals may indicate a specific immune defect
[59] occurring in the CAS-fed animals after exposure to
carcinogen and thereby contributing to enhanced tumor-
igenesis in this group.
Several microarray studies of human paired normal colon
vs. colon tumors have been published [60-64]. Compari-
son of the present results for normal colon tissue of AOM-
treated rats on different diets to the published studies for
human CRC identified only a small number of common
differentially expressed genes and/or gene families in
common (data not shown). This small number is proba-
bly due to the fact that our study did not examine colon
tumors; rather we focused on 'normal' colon tissue. In this
regard, it will be interesting to examine the expression
profiles of colons from animals not treated with AOM so
as to more specifically correlate transcripts with diet and
cancer phenotype. This study has illuminated a number of
genes and gene families that may act as dietary protein-
dependent modulators of oncogenesis in the rat colon.
Additional studies that specifically address the functional
involvement of these genes in cancer-prevention via die-
tary means are required to confirm the postulated roles.
Diet effects on serum Sst concentration Figure 4
Diet effects on serum Sst concentration. Values are mean ± 
SEM. One-way ANOVA. *P < 0.05, SPI or WPH vs. CAS.
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Conclusions
We have identified genes in rat colon that are differen-
tially expressed, as a consequence of altered dietary pro-
tein, during AOM-induced oncogenesis. These are
candidates for genes that sub-serve the anti-cancer effects
of dietary SPI and WPH in this tissue.
Methods
Rats, diets and carcinogen treatment
The animals whose colons were used in the present study
have been previously described [8,9]. Time-mated [gesta-
tion day (GD) 4] Sprague-Dawley rats were purchased
from Harlan Industries (Indianapolis, IN), housed
individually and allowed ad libitum access to water and
pelleted food. Rats were randomly assigned to one of
three semi-purified isocaloric diets made according to the
AIN-93G diet formula [65] and which differed only by
protein source: a) CAS (New Zealand Milk Products, Santa
Rosa, CA), b) WPH (New Zealand Milk Products, Santa
Rosa, CA) or c) SPI (Dupont Protein Technologies, St.
Louis, MO). Offspring were weaned to the same diet as
their mothers and were fed the same diets throughout the
study. At 90 days of age, male offspring received s.c. injec-
tions of 15 mg/kg AOM (Ash Stevens, Detroit, MI) in
saline once a week for 2 weeks. Forty weeks later, rats were
euthanized, and the colon (cecum to anus) was divided
into two equal segments (proximal and distal), opened
longitudinally, and examined for tumors. We found that
both WPH and SPI significantly decreased the colon
tumor incidence [data published in [8,9]]. A
representative non-tumor segment of each proximal
colon (PC) was frozen in liquid nitrogen and stored at -
80°C for later use. Animal care and handling were in
accordance with the Institutional Animal Care & Use
Committee guidelines of the University of Arkansas for
Medical Sciences.
RNA processing
Total RNA was isolated from rat proximal colons (n = 7
for each of CAS, SPI and WPH diets) using TRIzol reagent
(Invitrogen, Carlsbad, CA), and further purified with the
RNeasy Mini Kit (QIAGEN, Valencia, CA). To remove con-
taminating DNA, on-column DNA digestion with RNase-
Free DNase (QIAGEN) was performed. Integrity of iso-
lated RNAs was confirmed using the RNA 6000 Nano
LabChip kit with the Agilent 2100 Bioanalyzer System
(Agilent Biotechnologies, Palo Alto, CA). To reduce errors
due to biological variability, RNA samples were pooled as
proposed by Bakay et al [66]. Pooled RNA (equal amounts
of RNA from each of 7 animals; 8 ug total) was used for
cDNA synthesis using a T7-(deoxythymidine)24 primer
and Superscript II (Life Technologies, Inc., Gaithersburg,
MD). The resulting cDNA was used with the ENZO BioAr-
ray High Yield RNA Transcript labeling kit (ENZO,
Farmingdale, NY) to synthesize biotin-labeled cRNA. The
cRNA was purified on RNeasy spin columns (QIAGEN)
and subjected to chemical fragmentation (size range of 35
to 200 bp). Three replicate cRNA targets were made in par-
allel starting from each RNA pool.
Microarray procedures
Ten ug of cRNA was hybridized for 16 hours to an Affyme-
trix (Santa Clara, CA) rat U34A GeneChip (3 chips used
per diet group), followed by incubations with streptavi-
din-conjugated phycoerythrin, and then with polyclonal
anti-streptavidin antibody coupled to phycoerythrin. Fol-
lowing washing, GeneChips were scanned using an Agi-
lent GeneArray laser scanner. Images were analyzed using
Affymetrix MAS 5.0 software. Bacterial sequence-derived
probes on the arrays served as external controls for hybrid-
ization, whereas the housekeeping genes β-actin and
GAPDH served as endogenous controls and for monitor-
ing the quality of the RNA target. To compare array data
between GeneChips, we scaled the average of the
fluorescent intensities of all probes on each array to a con-
stant target intensity of 500.
Bioinformatics
To validate the microarray procedure for our samples,
unsupervised nearest-neighbor hierarchical clustering
(Spotfire, Somerville, MA) was performed on gene expres-
sion data. The inter-chip variability test also was per-
formed as specified in the Affymetrix data analysis manual
[28]. To identify colon genes differentially expressed with
SPI or WPH (control: CAS diet), multiple criteria were
applied; final results are reported only for transcripts that
passed all three analytical steps described below. Firstly,
the t-test feature of DMT (Affymetrix) was used to identify
genes whose expression was regulated (induced/repressed
with P < 0.05) by SPI or WPH, and signal fold changes
(FC) for these genes were calculated. Secondly, microarray
data were analyzed using 'Significance of Analysis of
Microarrays' (SAM, Stanford) to identify significant
changes in gene expression among diet groups [67], using
a false discovery rate (FDR) cutoff of 0.5%. Lastly, a pair-
wise comparison survival (3 × 3) method was used to
identify differentially expressed transcripts [68]. In brief,
the three replicate expression profiles obtained for SPI
colons were iteratively compared with the three CAS pro-
files (latter as baseline) in MAS 5.0 (Affymetrix), generat-
ing nine comparisons in total. Transcripts with a log ratio
greater than or equal to 1 (≥2 fold change), which
increased (I) in nine of nine comparisons, and which were
expressed above background (i.e., called as Present) in all
three SPI GeneChips, were considered to be up-regulated
by SPI. Transcripts with a log ratio less than or equal to -
1, were decreased (D) in nine of nine comparisons, and
expressed above background (Present) in all three CAS
chips were considered to be down-regulated by SPI. WPH-
regulated genes were similarly identified. Genes that wereMolecular Cancer 2005, 4:1 http://www.molecular-cancer.com/content/4/1/1
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independently identified by all three approaches com-
prised the final reported lists of differentially expressed
genes (Tables 2, 3, 4, 5, 6).
Validation of gene expression by quantitative real-time 
RT-PCR
One µg of total RNA from each of the 21 individual prox-
imal colons (which comprised the original pools for the
microarray experiment) was reverse-transcribed using ran-
dom hexamers and MultiScribe Reverse Transcriptase in a
two-step RT-PCR reaction (Applied Biosystems, Foster
City, CA). Primers (Table 7) were designed using 'Primer
Express' (Applied Biosystems) and were selected to yield a
single amplicon; this was verified by dissociation curves
and/or analysis in agarose gels. SYBR Green real-time PCR
was performed with an ABI Prism 7000 Sequence Detec-
tor. Thermal cycling conditions included pre-incubation
at 50°C for 2 min, 95°C for 10 min followed by 40 PCR
cycles at 95°C for 15 sec and 60°C for 1 min. The relative
transcript levels for each gene were calculated using the
relative standard curve method (User Bulletin #2, Applied
Biosystems) and normalized to the house-keeping gene β-
actin. Data are reported as mean ± SEM of n = 7 animals
per dietary group. Significant differences between diet
groups were determined by one-way ANOVA (P < 0.05).
Serum Sst
Rat serum Sst content (15 animals from each diet) was
determined using the somatostatin-28 EIA kit purchased
from Phoenix Pharmaceuticals Corporation (Belmont,
California).
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